In healthy infants and young children, the development of respiratory tract infections (RTIs) is extremely common. In this paper, we present an international consensus of the available approaches for the prevention of recurrent RTIs in children, including the atopic/allergic ones as well as those with asthma. Few convincing measures for reducing the frequency and clinical relevance of recurrent respiratory episodes in RTI-prone children have been developed until now. Among the most recently suggested measures, immunotherapy is attractive, but only for OM-85 is there a sufficient number of well-conducted clinical trials confirming efficacy in RTIs prevention with an adequate safety profile. In the case of probiotics, it is not clear which bacteria can offer the best results and which dosage and schedule of administration are the most effective. The problems of dosage and the schedule of administration are not solved also for vitamin D, despite some promising efficacy results. While we wait for new knowledge, the elimination or reduction as much as possible of the environmental factors that favor RTIs, vaccination when available and/or indicated, and the systematic application of the traditional methods for infection prevention, such as hand washing, remain the best measures to prevent recurrent infections in RTI-prone children.

Prevention of new respiratory episodes in children with recurrent respiratory infections: An expert consensus statement / Esposito, S.; Jones, M. H.; Feleszko, W.; Martell, J. A. O.; Falup-Pecurariu, O.; Geppe, N.; Martinon-Torres, F.; Shen, K. -L.; Roth, M.; Principi, N.. - In: MICROORGANISMS. - ISSN 2076-2607. - 8:11(2020), pp. 1-19. [10.3390/microorganisms8111810]

Prevention of new respiratory episodes in children with recurrent respiratory infections: An expert consensus statement

Esposito S.;
2020-01-01

Abstract

In healthy infants and young children, the development of respiratory tract infections (RTIs) is extremely common. In this paper, we present an international consensus of the available approaches for the prevention of recurrent RTIs in children, including the atopic/allergic ones as well as those with asthma. Few convincing measures for reducing the frequency and clinical relevance of recurrent respiratory episodes in RTI-prone children have been developed until now. Among the most recently suggested measures, immunotherapy is attractive, but only for OM-85 is there a sufficient number of well-conducted clinical trials confirming efficacy in RTIs prevention with an adequate safety profile. In the case of probiotics, it is not clear which bacteria can offer the best results and which dosage and schedule of administration are the most effective. The problems of dosage and the schedule of administration are not solved also for vitamin D, despite some promising efficacy results. While we wait for new knowledge, the elimination or reduction as much as possible of the environmental factors that favor RTIs, vaccination when available and/or indicated, and the systematic application of the traditional methods for infection prevention, such as hand washing, remain the best measures to prevent recurrent infections in RTI-prone children.
2020
Prevention of new respiratory episodes in children with recurrent respiratory infections: An expert consensus statement / Esposito, S.; Jones, M. H.; Feleszko, W.; Martell, J. A. O.; Falup-Pecurariu, O.; Geppe, N.; Martinon-Torres, F.; Shen, K. -L.; Roth, M.; Principi, N.. - In: MICROORGANISMS. - ISSN 2076-2607. - 8:11(2020), pp. 1-19. [10.3390/microorganisms8111810]
File in questo prodotto:
File Dimensione Formato  
Prevention of New Respiratory Episodes in Children.pdf

accesso aperto

Tipologia: Versione (PDF) editoriale
Licenza: Creative commons
Dimensione 356.22 kB
Formato Adobe PDF
356.22 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2887959
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 23
social impact